Synopsis
Synopsis
0
KDMF
0
VMF
0
FDF
0
Canada
0
South Africa
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. E-mycin E
2. Emycin E
3. Eryped
4. Erythroped
5. Ethyl Succinate, Eyrthromycin
6. Ethylsuccinate, Erythromycin
7. Eyrthromycin Ethyl Succinate
8. Monomycin
9. Pediamycin
10. Succinate, Eyrthromycin Ethyl
11. Wyamycin E
1. 1264-62-6
2. Erythroped
3. Pediamycin
4. Eryped
5. Wyamycin E
6. Erythromycin Ethyl Succinate
7. Erythromycin, 2'-(ethyl Butanedioate)
8. Wyamycin
9. Erythromycin 2'-(ethyl Butanedioate)
10. E.e.s.
11. Mls001074901
12. 41342-53-4
13. Nsc-756758
14. Erythromycin-ethyl Succinate
15. Succinic Acid, Monoethyl Ester, Monoester With Erythromycin
16. Chebi:31555
17. Erythrocin Ethyl Succinate
18. 1014ksj86f
19. E-mycin E
20. Smr000058868
21. Erythromycin 2'-(ethyl Succinate)
22. Anamycin
23. Arpimycin
24. Ery-ped
25. Pediamycin 400
26. Ees Granules
27. E.e.s
28. Erythromycin, Ethyl Succinate
29. Ees (antiobiotic)
30. Hsdb 3075
31. Erythromycin Ethylsuccinate [jan]
32. Erythromycin, Mono(ethyl Succinate)
33. Einecs 215-033-8
34. Brn 0077638
35. Esinol
36. Unii-1014ksj86f
37. Erythromycin, Mono(ethyl Succinate) (ester)
38. Ncgc00183038-01
39. E-mycin-e
40. E.e.s 200
41. E.e.s 400
42. Eryped (tn)
43. Durapaediat
44. Eryliquid
45. Refkas
46. Erythrocin W (tn)
47. Erythromycin Ethylsuccinate [usp:jan]
48. Spectrum_001046
49. Spectrum2_000983
50. Spectrum3_000419
51. Spectrum4_000536
52. Spectrum5_000668
53. Erythromycin-ethylsuccinate
54. Dsstox_cid_2993
55. Dsstox_rid_76821
56. Dsstox_gsid_22993
57. Erythromycin A Ethylsuccinate
58. Schembl18259
59. Bspbio_001978
60. Kbiogr_001171
61. Kbioss_001526
62. 4-18-00-07416 (beilstein Handbook Reference)
63. Mls000028651
64. Mls001076672
65. Succinicacid,monoethylester,monoesterwitherythromycin
66. Divk1c_000764
67. Spectrum1500279
68. Spbio_001045
69. Cid_443953
70. Chembl1200688
71. Dtxsid4022993
72. Bdbm96262
73. E.e.s. (tn)
74. Hms502g06
75. Kbio1_000764
76. Kbio2_001526
77. Kbio2_004094
78. Kbio2_006662
79. Kbio3_001198
80. Ninds_000764
81. Sterile Erythromycin Ethylsuccinate
82. Hms1923i21
83. Hms2091d03
84. Pharmakon1600-01500279
85. Erithromycin Ethyl Succinate
86. Hy-b0957
87. 2'-(ethyl Butanedioate)erythromycin
88. Tox21_113497
89. Ccg-40201
90. Lmpk05000001
91. Mfcd00084692
92. Nsc756758
93. S4060
94. Akos008145410
95. Zinc169356230
96. Cs-4434
97. Nsc 756758
98. Erythromycin Ethylsuccinate (jp17/usp)
99. Erythromycin Ethylsuccinate [mi]
100. Idi1_000764
101. Erythromycin (as Ethyl Succinate)
102. Ncgc00021382-03
103. 4-o-[(2s,3r,4s,6r)-4-(dimethylamino)-2-[[(3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] 1-o-ethyl Butanedioate
104. Erythromycin Ethylsuccinate [hsdb]
105. Cas-1264-62-6
106. Erythromycin Ethylsuccinate [vandf]
107. Sbi-0051367.p003
108. Erythromycin Ethylsuccinate [usp-rs]
109. Erythromycin Ethylsuccinate [who-dd]
110. Erythromycin Ethylsuccinate [who-ip]
111. Erythromycin Ethyl Succinate [mart.]
112. D01361
113. Ab00051980_11
114. Ab00051980_12
115. Erythromycin Ethylsuccinate [orange Book]
116. A805556
117. Erythromycin Ethylsuccinate [ep Monograph]
118. Erythromycin Ethylsuccinate [usp Monograph]
119. Erythromycini Ethylsuccinas [who-ip Latin]
120. Sr-05000001617
121. Eryzole Component Erythromycin Ethylsuccinate
122. Sr-05000001617-1
123. Erythromycin Ethylsuccinate Component Of Eryzole
124. Pediazole Component Erythromycin Ethylsuccinate
125. Q27114406
126. Erythromycin Ethylsuccinate Component Of Pediazole
127. Erythromycin Ethylsuccinate For Impurity P Identification
128. Sterile Erythromycin Ethylsuccinate [usp Monograph]
129. Oxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] 1-o-ethyl Butanedioate
130. (2s,3r,4s,6r)-4-(dimethylamino)-2-(((3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-14-ethyl-7,12,13-trihydroxy-4-(((2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecan-6-yl)oxy)-6-methyltetrahydro-2h-pyran-3-yl Ethyl Succinate
131. (3r*,4s*,5s*,6r*,7r*,9r*,11r*,12r*,13s*,14r*)-4-((2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((2- Ethyl Butanedioate -3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione
132. 4-o-[(2s,3r,4s,6r)-4-(dimethylamino)-2-[[(3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-di
133. O4-[(2s,3r,4s,6r)-4-(dimethylamino)-2-[[(3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyl-tetrahydropyran-3-yl] O1-ethyl Butanedioate
Molecular Weight | 862.1 g/mol |
---|---|
Molecular Formula | C43H75NO16 |
XLogP3 | 3.4 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 17 |
Rotatable Bond Count | 14 |
Exact Mass | 861.50858530 g/mol |
Monoisotopic Mass | 861.50858530 g/mol |
Topological Polar Surface Area | 226 Ų |
Heavy Atom Count | 60 |
Formal Charge | 0 |
Complexity | 1450 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 18 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 12 | |
---|---|
Drug Name | E.e.s. 200 |
Active Ingredient | Erythromycin ethylsuccinate |
Dosage Form | Suspension |
Route | Oral |
Strength | eq 200mg base/5ml |
Market Status | Prescription |
Company | Arbor Pharms |
2 of 12 | |
---|---|
Drug Name | E.e.s. 400 |
Active Ingredient | Erythromycin ethylsuccinate |
Dosage Form | Tablet; Suspension |
Route | Oral |
Strength | eq 400mg base/5ml; eq 400mg base |
Market Status | Prescription |
Company | Arbor Pharms |
3 of 12 | |
---|---|
Drug Name | Eryped |
Active Ingredient | Erythromycin ethylsuccinate |
Dosage Form | Granule |
Route | Oral |
Strength | eq 400mg base/5ml; eq 200mg base/5ml |
Market Status | Prescription |
Company | Arbor Pharms |
4 of 12 | |
---|---|
Drug Name | Erythromycin ethylsuccinate |
Drug Label | Erythromycin is produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids. The base, the stearate salt, and the esters are... |
Active Ingredient | Erythromycin ethylsuccinate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 400mg base |
Market Status | Prescription |
Company | Arbor Pharms |
5 of 12 | |
---|---|
Drug Name | Pediamycin |
Active Ingredient | Erythromycin ethylsuccinate |
Dosage Form | Suspension |
Route | Oral |
Strength | eq 200mg base/5ml |
Market Status | Prescription |
Company | Arbor Pharms |
6 of 12 | |
---|---|
Drug Name | Pediamycin 400 |
Active Ingredient | Erythromycin ethylsuccinate |
Dosage Form | Suspension |
Route | Oral |
Strength | eq 400mg base/5ml |
Market Status | Prescription |
Company | Arbor Pharms |
7 of 12 | |
---|---|
Drug Name | E.e.s. 200 |
Active Ingredient | Erythromycin ethylsuccinate |
Dosage Form | Suspension |
Route | Oral |
Strength | eq 200mg base/5ml |
Market Status | Prescription |
Company | Arbor Pharms |
8 of 12 | |
---|---|
Drug Name | E.e.s. 400 |
Active Ingredient | Erythromycin ethylsuccinate |
Dosage Form | Tablet; Suspension |
Route | Oral |
Strength | eq 400mg base/5ml; eq 400mg base |
Market Status | Prescription |
Company | Arbor Pharms |
9 of 12 | |
---|---|
Drug Name | Eryped |
Active Ingredient | Erythromycin ethylsuccinate |
Dosage Form | Granule |
Route | Oral |
Strength | eq 400mg base/5ml; eq 200mg base/5ml |
Market Status | Prescription |
Company | Arbor Pharms |
10 of 12 | |
---|---|
Drug Name | Erythromycin ethylsuccinate |
Drug Label | Erythromycin is produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics. It is basic and readily forms salts with acids. The base, the stearate salt, and the esters are... |
Active Ingredient | Erythromycin ethylsuccinate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 400mg base |
Market Status | Prescription |
Company | Arbor Pharms |
11 of 12 | |
---|---|
Drug Name | Pediamycin |
Active Ingredient | Erythromycin ethylsuccinate |
Dosage Form | Suspension |
Route | Oral |
Strength | eq 200mg base/5ml |
Market Status | Prescription |
Company | Arbor Pharms |
12 of 12 | |
---|---|
Drug Name | Pediamycin 400 |
Active Ingredient | Erythromycin ethylsuccinate |
Dosage Form | Suspension |
Route | Oral |
Strength | eq 400mg base/5ml |
Market Status | Prescription |
Company | Arbor Pharms |
Antibiotics, Macrolide; Enzyme Inhibitors; Gastrointestinal Agents; Protein Synthesis Inhibitors
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
RELATIVELY NONIRRITATING...& THUS IS WELL SUITED TO IM INJECTION. ...ITS ACTIONS & USES ARE ESSENTIALLY THOSE OF ERYTHROMYCIN...INTO WHICH IT IS CONVERTED IN THE BODY.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1123
ERYTHROMYCIN IS...ANTIMICROBIAL... ERYTHROMYCIN IS.../ACTIVE/ AGAINST MOST GRAM-POSITIVE BACTERIA, MANY ANAEROBES...& LEGIONNAIRE'S BACILLUS. /ERYTHROMYCIN/
Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 55
ERYTHROMYCIN MAY BE...BACTERIOSTATIC OR BACTERICIDAL DEPENDING ON NATURE OF MICROORGANISM & CONCN OF DRUG. ...MOST EFFECTIVE IN VITRO AGAINST GRAM-POSITIVE COCCI SUCH AS STAPHYLOCOCCUS AUREUS (PENICILLIN G SENSITIVE OR RESISTANT), GROUP A STREPTOCOCCI, ENTEROCOCCI & PNEUMOCOCCI; MANY GRAM-POSITIVE BACILLI... /ERYTHROMYCIN/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1224
A REVIEW OF THE ANTIMICROBIAL SPECTRUM, PHARMACOLOGY & THERAPEUTIC USE OF ERYTHROMYCIN & ITS DERIVATIVES. (REF 24).
MEADE RH; DRUG THERAPY REVIEWS; ANTIMICROBIAL SPECTRUM, PHARMACOLOGY & THERAPEUTIC USE OF ERYTHROMYCIN & ITS DERIVATIVES; AM J HOSP PHARM 36, SEPT 1979, 1185-1189
Gastrointestinal Agents
Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
ERYTHROMYCIN ETHYLSUCCINATE IS PARTIALLY DISSOCIATED IN INTESTINE; BOTH ERYTHROMYCIN & UNDISSOCIATED ESTER ARE ABSORBED &, IN THE BLOOD, THE ESTER IS HYDROLYZED TO RELEASE FREE ERYTHROMYCIN.
Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 54
ERYTHROMYCIN ETHYLSUCCINATE...IS ADEQUATELY ABSORBED FOLLOWING ORAL ADMINISTRATION, PARTICULARLY WHEN THE STOMACH IS EMPTY. PEAK CONCENTRATIONS IN PLASMA ARE 1.5 UG/ML (0.5 UG/ML OF BASE) 1 TO 2 HR AFTER ADMINISTRATION OF A 500 MG TABLET.
Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1223
IN PATIENTS, MEAN BILE LEVELS OF ERYTHROMYCIN WERE APPROXIMATELY 10 TIMES HIGHER THAN CORRESPONDING SERUM CONCN 1 HR AFTER IV (ERYTHROMYCIN LACTOBIONATE) & IM (ERYTHROMYCIN SUCCINATE) INJECTION.
CHELVAN P ET AL; BILIARY EXCRETION OF ERYTHROMYCIN AFTER PARENTERAL ADMINISTRATION; BR J CLIN PHARMACOL 8(3) 233 (1979)
IN HEALTHY ADULT SUBJECTS & IN ADULT PATIENTS WITH BRONCHIAL INFECTIONS, PHARMACOKINETICS OF VARIOUS FORMULATIONS OF ERYTHROMYCIN WERE STUDIED. ERYTHROMYCIN ETHYLSUCCINATE WAS BETTER THAN ERYTHROMYCIN STEARATE FOR ORAL TREATMENT IN THAT IT WAS RAPIDLY & CONSISTENTLY ABSORBED.
SIMON C; CURR MED RES OPIN 6(8) 17 (1980)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Erythromycin Ethyl Succinate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Erythromycin Ethyl Succinate, including repackagers and relabelers. The FDA regulates Erythromycin Ethyl Succinate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Erythromycin Ethyl Succinate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Erythromycin Ethyl Succinate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Erythromycin Ethyl Succinate supplier is an individual or a company that provides Erythromycin Ethyl Succinate active pharmaceutical ingredient (API) or Erythromycin Ethyl Succinate finished formulations upon request. The Erythromycin Ethyl Succinate suppliers may include Erythromycin Ethyl Succinate API manufacturers, exporters, distributors and traders.
click here to find a list of Erythromycin Ethyl Succinate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Erythromycin Ethyl Succinate DMF (Drug Master File) is a document detailing the whole manufacturing process of Erythromycin Ethyl Succinate active pharmaceutical ingredient (API) in detail. Different forms of Erythromycin Ethyl Succinate DMFs exist exist since differing nations have different regulations, such as Erythromycin Ethyl Succinate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Erythromycin Ethyl Succinate DMF submitted to regulatory agencies in the US is known as a USDMF. Erythromycin Ethyl Succinate USDMF includes data on Erythromycin Ethyl Succinate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Erythromycin Ethyl Succinate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Erythromycin Ethyl Succinate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Erythromycin Ethyl Succinate Drug Master File in Japan (Erythromycin Ethyl Succinate JDMF) empowers Erythromycin Ethyl Succinate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Erythromycin Ethyl Succinate JDMF during the approval evaluation for pharmaceutical products. At the time of Erythromycin Ethyl Succinate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Erythromycin Ethyl Succinate suppliers with JDMF on PharmaCompass.
A Erythromycin Ethyl Succinate CEP of the European Pharmacopoeia monograph is often referred to as a Erythromycin Ethyl Succinate Certificate of Suitability (COS). The purpose of a Erythromycin Ethyl Succinate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Erythromycin Ethyl Succinate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Erythromycin Ethyl Succinate to their clients by showing that a Erythromycin Ethyl Succinate CEP has been issued for it. The manufacturer submits a Erythromycin Ethyl Succinate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Erythromycin Ethyl Succinate CEP holder for the record. Additionally, the data presented in the Erythromycin Ethyl Succinate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Erythromycin Ethyl Succinate DMF.
A Erythromycin Ethyl Succinate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Erythromycin Ethyl Succinate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Erythromycin Ethyl Succinate suppliers with CEP (COS) on PharmaCompass.
A Erythromycin Ethyl Succinate written confirmation (Erythromycin Ethyl Succinate WC) is an official document issued by a regulatory agency to a Erythromycin Ethyl Succinate manufacturer, verifying that the manufacturing facility of a Erythromycin Ethyl Succinate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Erythromycin Ethyl Succinate APIs or Erythromycin Ethyl Succinate finished pharmaceutical products to another nation, regulatory agencies frequently require a Erythromycin Ethyl Succinate WC (written confirmation) as part of the regulatory process.
click here to find a list of Erythromycin Ethyl Succinate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Erythromycin Ethyl Succinate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Erythromycin Ethyl Succinate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Erythromycin Ethyl Succinate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Erythromycin Ethyl Succinate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Erythromycin Ethyl Succinate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Erythromycin Ethyl Succinate suppliers with NDC on PharmaCompass.
Erythromycin Ethyl Succinate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Erythromycin Ethyl Succinate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Erythromycin Ethyl Succinate GMP manufacturer or Erythromycin Ethyl Succinate GMP API supplier for your needs.
A Erythromycin Ethyl Succinate CoA (Certificate of Analysis) is a formal document that attests to Erythromycin Ethyl Succinate's compliance with Erythromycin Ethyl Succinate specifications and serves as a tool for batch-level quality control.
Erythromycin Ethyl Succinate CoA mostly includes findings from lab analyses of a specific batch. For each Erythromycin Ethyl Succinate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Erythromycin Ethyl Succinate may be tested according to a variety of international standards, such as European Pharmacopoeia (Erythromycin Ethyl Succinate EP), Erythromycin Ethyl Succinate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Erythromycin Ethyl Succinate USP).
LOOKING FOR A SUPPLIER?